Primary Care Update Kauai - On Demand CME

Primary Care Update Kauai - On Demand CME is organized by University Learning Systems (ULS).

Session 1: New Drugs, Obesity, COPD, Fibromyalgia
New Drugs Part 1

• Identify 10 – 20 new medications.
• Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.
• Discuss updates related to labeling, indications, and risks associated with various medications

Obesity Case Studies:

• Discuss the health risks associated with obesity.
• Identify the various behavioral modalities utilized to assist with weight loss.
• Discuss pharmacologic strategies for weight stabilization or loss in the overweight or obese individual

COPD

• Identify statistics regarding COPD.
• Discuss the signs and symptoms of COPD.
• Discuss treatment options for COPD.

Fibromyalgia

• Identify new diagnostic criteria for fibromyalgia.
• Discuss the various non-pharmacologic and pharmacologic treatments available for individuals with fibromyalgia.
• Review multimodal treatments based on the evidence.

Session 2: New Drugs, Pediatric Pharmacotherapeutics, CKD Treatment in Primary Care
New Drugs Part 2

• Identify 10 – 20 new medications
• Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.
• Discuss updates related to labeling, indications, and risks associated with various medications.

Pediatric Pharmacotherapeutics: 

• Identify ways in which children are different than adults in terms of pharmacotherapeutics
• Discuss common pediatric prescribing errors.
• Discuss strategies to prevent pediatric prescribing errors.
• Identify medications with new pediatric approvals.

COVID–Drug Interactions

• Improve the ability to identify disparity gaps in treatment, management, and drug interactions in outpatients with COVID-19.
• Gain greater confidence in their ability to assess and manage outpatients with COVID-19 for drug interactions.
• Enhance their understanding of the national COVID-19 Treatment Guidelines for outpatients with COVID-19.

CKD Treatment in Primary Care

• Detect and recognize CKD in patients with reduced kidney function, including in the early stages of disease.
• Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible.
• Initiate therapy with evidence-based therapies, including newer agents, for patients with CKD when indicated.

Session 3: Respiratory Infections, Resistant Hypertension, OA and RA Guidelines 2023, Immunizations

Antibiotic Update: Respiratory Infections:

• Identify statistics related to incidence/prevalence of various respiratory conditions.
• Discuss the signs and symptoms of pneumonia, ABRS, AOM, AECB.
• Discuss treatment pharmacologic options for the above conditions.

New Therapies for Resistant Hypertension:

• Discuss the definition of resistant hypertension.
• Identify the work up for the patient with resistant hypertension.
• Discuss the treatment options for patient with resistant hypertension.

OA and RA Guidelines 2023

• Discuss the pathophysiology of osteoarthritis and rheumatoid arthritis.
• Identify the non-pharmacologic and pharmacologic agents available for the treatment of osteoarthritis and RA.
• Compare and contrast newer pharmacologic agents with older agents with regard to benefits, risks, side effects, and drug interactions.

Immunizations:

• Identify the 2024 recommended vaccinations and schedule for individuals across the lifespan.
• Discuss the benefits and side effects of the various vaccines for individuals across the lifespan.
• Discuss strategies to improve vaccine hesitancy